Article
Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
Diagnostic molecular pathology : the American journal of surgical pathology, part B - 1 Mar 2012
Halait Harkanwal, Demartin Kelli, Shah Sweta, Soviero Stephen, Langland Rachel, Cheng Suzanne, Hillman Grantland, Wu Lin, Lawrence H Jeffrey
Abstract excerpt
Melanomas frequently harbor BRAFV600 mutations. Vemurafenib (RG7204/PLX4032), a small-molecule inhibitor of mutant BRAF, has shown striking clinical efficacy in BRAFV600 mutant melanoma, creating the need for a well-validated companion diagnostic to select patients for treatment. We describe analytic performance characteristics of the cobas 4800 BRAF V600 Mutation Test, the test used to select patients for the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.